Intra-Cellular Therapies (ITCI) Highlights Data on Symptom Improvement by Lumateperone on Negative Symptoms, Depression & Social Function in Patients with Schizophrenia
Tweet Send to a Friend
Intra-Cellular Therapies, Inc. (NAsDAQ: ITCI) announced presentations on lumateperone at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting in ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
